HDL Therapeutics Secures $1,486,610 New Round

  • Feed Type
  • Date
    9/15/2016
  • Company Name
    HDL Therapeutics
  • Mailing Address
    46701 Commerce Center Drive Plymouth, MI 48170 USA
  • Company Description
    We are a privately held cardiovascular device company and a leader in the field of reversing coronary atherosclerosis. Our innovative acute care therapeutic device called PDS-2™ System transforms a patient’s own plasma into an atherosclerostic reversal agent using our patented technology.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,486,610
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. 13 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy